wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q36305457-88925FAD-F6B2-4388-84A8-966324C58415
Q36305457-88925FAD-F6B2-4388-84A8-966324C58415
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36305457-88925FAD-F6B2-4388-84A8-966324C58415
Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?
P2860
Q36305457-88925FAD-F6B2-4388-84A8-966324C58415
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36305457-88925FAD-F6B2-4388-84A8-966324C58415
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
b8b511231d4aaea6c56eb14eadee15f22794c92e
P2860
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).